Clinical trials: Bacterial Pneumonia
Hospital Acquired Bacterial Pneumonia, Complicated Skin and Skin Structure Infections
Telavancin Observational Use Registry (TOUR)
The telavancin observational use registry (TOUR) will collect data to support study of the efficacy, safety, and pattern of use of telavancin in hospital-based inpatients and in outpatients being treated in infusion centers who…
- Conditions
- Hospital Acquired Bacterial Pneumonia, Complicated Skin and Skin Structure Infections, Ventilator Associated Bacterial Pneumonia, Gram Positive Infection
- Trial name
- TOUR (NCT02288234)
- Testing
- Vibativ
- Where
- United States
- Volunteers
- 1,063 people
- Sponsor
- Cumberland Pharmaceuticals
Pneumonia, Bacterial, Pneumococcal Infections
A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
This is a Phase 2 clinical study evaluating AFX3772 in healthy infants for the prevention of pneumococcal disease. The purpose of this study is to determine the safety, tolerability, and immunogenicity of three different…
- Conditions
- Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
- Trial name
- NCT05412030
- Testing
- AFX3772, Prevnar 13, Prevnar 20
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Community-acquired Pneumonia
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
The purpose of this study is to evaluate the pharmacokinetics of an oral omadacycline dosing regimen in the treatment of adults with CABP.
- Trial name
- NCT04160260
- Testing
- Omadacycline
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- Paratek Pharmaceuticals Inc
Pneumonia, Pneumococcal Infections
Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae
The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous…
- Trial name
- NCT02583373
- Testing
- CAL02 Low-dose, CAL02 High-dose
- Where
- 10 sites in Belgium, France
- Volunteers
- 19 people
- Sponsor
- Combioxin SA
Pneumonia, Bacterial
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and…
- Trial name
- INHALE 1 (NCT01799993)
- Testing
- Amikacin Inhalation Solution (BAY41-6551)
- Where
- 65 sites in United States, Australia and 10 more
- Volunteers
- 725 people
- Sponsor
- Bayer
Pneumococcal Infections, Streptococcus Pneumoniae Infections
Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults
This study is designed to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adult volunteers.
- Conditions
- Pneumococcal Infections, Streptococcus Pneumoniae Infections, Pneumococcal Pneumonia
- Trial name
- NCT01444352
- Testing
- Pneumococcal vaccine Formulation 1, Pneumococcal vaccine Formulation 2, Pneumococcal vaccine Formulation 3
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Infections
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
The purpose of this study is to determine whether ceftaroline is effective and safe for the treatment of patients with Community-acquired Bacterial Pneumonia (CABP) at risk for infection due to Methicillin-resistant…
- Trial name
- NCT01645735
- Testing
- Ceftaroline fosamil, Ceftriaxone plus vancomycin
- Where
- 31 sites in United States, Georgia and 6 more
- Volunteers
- 49 people
- Sponsor
- Forest Laboratories
Pneumonia, Pneumococcal, Diabetes Mellitus
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
Primary care visits are a key aspect of clinical care focused on helping patients to close care gaps related to preventive care such as vaccination, diabetes testing, statin therapy and cancer screening.
- Conditions
- Pneumonia, Pneumococcal, Diabetes Mellitus, Breast Cancer, Colorectal Cancer
- Trial name
- NCT05799976
- Testing
- Text message nudge
- Where
- United States
- Volunteers
- 29,334 people, healthy volunteers welcome
- Sponsor
- Mitesh Patel
SARS-CoV-2 Infection, Bacterial Respiratory Tract Infection
Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2
This is a longitudinal, prospective observational study focusing on health-related outcomes relative to potential changes in the respiratory microbiome seen with weekly SARS-CoV-2 testing in nursing home residents.
- Conditions
- SARS-CoV-2 Infection, Bacterial Respiratory Tract Infection, Viral Respiratory Tract Infection
- Trial name
- COVID-19 (NCT04815018)
- Where
- 4 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Pathnostics
Community-acquired Pneumonia, Bacterial Pneumonia
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
- Trial name
- NCT04779242
- Testing
- Omadacycline, Moxifloxacin
- Where
- 55 sites in Bulgaria, Croatia and 6 more
- Volunteers
- 670 people
- Sponsor
- Paratek Pharmaceuticals Inc
Mycoplasma Pneumoniae Pneumonia
Effect of Probiotics on Mycoplasma Pneumoniae Pneumonia
To evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with mycoplasma pneumoniae pneumonia, in comparison with placebo.
- Trial name
- NCT06348095
- Testing
- Probiotic
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wecare Probiotics Co., Ltd.
Pneumonia, Pneumococcal
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
This a study of V116 in adults ≥50 years of age who concomitantly received Influenza vaccine. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116 when administered…
- Trial name
- NCT05526716
- Testing
- V116, QIV
- Where
- 56 sites in United States
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease.
- Trial name
- CARE-CF1 (NCT03000348)
- Testing
- Cysteamine
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 91 people
- Sponsor
- NovaBiotics Ltd.
Pneumonia, Pneumocystis Carinii, HIV Infections
A Treatment IND for 566C80 Therapy of Pneumocystis Carinii Pneumonia
To facilitate provision of atovaquone (566C80) to patients who have mild to moderate Pneumocystis carinii pneumonia (PCP) and are intolerant and/or unresponsive to trimethoprim / sulfamethoxazole (TMP / SMX ); to monitor serious…
- Trial name
- NCT00001991
- Testing
- Atovaquone
- Where
- United States
- Sponsor
- Glaxo Wellcome
Staphylococcus Aureus Pneumonia
Study of the Efficacy and Safety of MEDI4893
Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
- Trial name
- SAATELLITE (NCT02296320)
- Testing
- MEDI4893
- Where
- 49 sites in United States, Belgium and 8 more
- Volunteers
- 213 people
- Sponsor
- MedImmune LLC
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
To evaluate the all-cause mortality rate at Day 28 in the YK-1169 group versus the ceftazidime-avibatan injection group in the mITT population.
- Trial name
- NCT07634198
- Testing
- YK-1169, Ceftazidime-avibactam Injection
- Volunteers
- 590 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Pneumonia, Community-Acquired, Bacterial Pneumonia
Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
The goal of this clinical trial is to evaluate the efficacy and safety of faropenem in comparison to co-amoxiclav and clarithromycin in Bangladeshi adults diagnosed with community-acquired bacterial pneumonia (CABP).
- Trial name
- NCT06804096
- Testing
- Faropenem, Co-amoxiclav, Clarithromycin 500 mg
- Where
- 2 sites in Bangladesh
- Volunteers
- 129 people
- Sponsor
- Dr. Md. Alimur Reza
Pneumonia, Pneumocystis Carinii, HIV Infections
A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia
To evaluate the safety and efficacy of trimetrexate glucuronate with leucovorin protection in European patients with Pneumocystis carinii pneumonia (PCP) who are refractory to or have demonstrated severe or life-threatening…
- Trial name
- NCT00002103
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Sponsor
- U.S. Bioscience
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia
- Trial name
- CAP (NCT00621504)
- Testing
- Ceftaroline fosamil for Injection, IV Ceftriaxone, Clarithromycin
- Where
- 168 sites in United States, Argentina and 21 more
- Volunteers
- 606 people
- Sponsor
- Forest Laboratories
Influenza, Human, Pneumonia, Pneumococcal
Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4
Subjects will be recruited and divided into 3 groups: Experimental Group (468 subjects): 1st dose : combined vaccination of COVAX+PPV23, 2nd dose: combined vaccination of COVAX+IIV4; Control Group A (468 subjects): 1st dose…
- Conditions
- Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia
- Trial name
- NCT05079152
- Testing
- COVAX+PPV23;COVAX+IIV4, COVAX only (1st and 2nd dose), PPV23 for the 1st dose and IIV4 for the 2nd dose
- Where
- 3 sites in China
- Volunteers
- 1,404 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited